Retatrutide Retatrutide PRODUCT IMAGE
HPLC VERIFIED CoA SUPPLIED ≥99% PURITY
★★★★★ Reviews
— Metabolic

Retatrutide GLP-1 / GIP / Glucagon Triple Agonist

For in vitro research use only. Retatrutide is not for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.

Retatrutide is a synthetic peptide that activates three different metabolic receptors (specialised docking points on cells) at the same time: GLP-1, GIP, and glucagon receptors. Each of these is involved in how the body manages energy, responds to insulin (the hormone that controls blood sugar), and processes fat. By targeting all three at once, it gives researchers a tool for studying how these pathways work together.

CAS Number
2381089-83-2
Molecular Formula
Synthetic peptide (MW 4731.3 Da)
HPLC Purity
≥99% (batch-verified)
Form
Lyophilised powder
Storage
2–8°C, desiccated, protected from light
Classification
Research reagent — in vitro use only
≥99%
HPLC purity
3rd-Party Tested
Independent lab
CoA Every Order
Batch-specific
Tracked 24
Royal Mail UK
Pay by Bank
No card stored

Research overview

Retatrutide is a synthetic peptide engineered to act as a triple agonist at three distinct G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This multi-receptor profile is structurally and pharmacologically distinct from single-agonist (GLP-1R only, e.g. semaglutide) and dual-agonist (GLP-1R/GIPR, e.g. tirzepatide) compounds — the simultaneous activation of all three metabolic receptor pathways provides researchers with a tool for studying combined receptor interactions in metabolic signalling that cannot be replicated with simpler agonist compounds.

Preclinical research on triple GLP-1/GIP/glucagon agonists has examined their effects on energy expenditure, adipose tissue lipolysis, hepatic glucose output, and pancreatic beta cell function. The GLP-1R component is associated with insulin secretion and gastric motility research; the GIPR component with insulin potentiation and lipid metabolism studies; and the glucagon receptor component with energy expenditure and hepatic glycogenolysis. Studies have examined how simultaneous agonism across all three receptors produces additive or synergistic effects on metabolic markers in rodent models, including adiposity, glucose tolerance, and lipid panels.

As the most pharmacologically complex compound in the Velox Peptides catalogue, Retatrutide is primarily of interest to researchers studying multi-receptor metabolic signalling, incretin biology, and energy homeostasis. Its availability in multiple vial sizes (10mg, 15mg, 20mg, 40mg) supports both cell culture and more extensive preclinical study designs. Velox Peptides supplies Retatrutide at ≥99% HPLC-verified purity as a lyophilised research reagent with batch certificate of analysis. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.

📖  Retatrutide Research Hub — 7 guides
Research Overview Mechanism of Action: GLP-1/GIP/Glucagon Clinical Research: Phase 1 & Phase 2 Data vs Tirzepatide & Semaglutide vs Ozempic (Semaglutide) vs Wegovy (Semaglutide) UK Research Grade: LY3437943

Compound specifications

Common nameRetatrutide
Full nameGLP-1 / GIP / Glucagon Triple Agonist
CAS number2381089-83-2
Molecular formulaSynthetic peptide (MW 4731.3 Da)
Molecular weight4731.3 g/mol
SequenceModified 39-aa peptide — triple agonist
HPLC purity≥99% (batch-verified)
AppearanceWhite to off-white lyophilised powder
SolubilityBacteriostatic water, sterile saline
Storage (lyophilised)2–8°C, protected from light
Storage (reconstituted)2–8°C, up to 28 days
Supplied as10mg, 15mg, 20mg, 40mg Pen

Batch testing and certificate of analysis

Every batch of Retatrutide is third-party HPLC-tested prior to dispatch. Batch documentation is available on request.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact support@veloxpeps.com.

Frequently Asked Research-Use Questions

What purity is Velox Peptides Retatrutide?
Retatrutide is supplied at ≥99% HPLC-verified purity. Batch documentation is available on request.
How is Retatrutide supplied and reconstituted for research use?
Retatrutide is supplied as a lyophilised powder in sterile single-use vials. For in vitro research use, reconstitution is performed with bacteriostatic water. See the reconstitution calculator for volume calculations based on required concentration.
What is Retatrutide used for in preclinical research?
Retatrutide is studied in the peer-reviewed literature across the pathways described in the research overview above. Velox Peptides supplies Retatrutide strictly as a research reagent for in vitro use by qualified researchers. It is not a medicinal product and is not for human or veterinary consumption.
Is Retatrutide legal to buy in the UK?
Yes. Research peptides including Retatrutide are lawful to purchase in the United Kingdom strictly for legitimate in vitro scientific research purposes. They are not controlled substances under UK law and are not subject to prescription requirements when purchased for research use. Velox Peptides supplies Retatrutide solely as a research reagent to qualified researchers. Buyers are responsible for ensuring all use complies with applicable law and with Velox Peptides’ Research Use Policy.
How does Retatrutide differ from semaglutide or tirzepatide as a research compound?
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist, whereas semaglutide is a single GLP-1R agonist and tirzepatide is a dual GLP-1R/GIPR agonist. The additional glucagon receptor (GCGR) agonism in Retatrutide provides a distinct pharmacological profile for research, particularly for studies examining energy expenditure and hepatic metabolic pathways that are not fully accessible with GLP-1R or GLP-1R/GIPR agonism alone. This makes Retatrutide a useful research tool for comparative receptor pharmacology studies in metabolic research.
How quickly is my order dispatched and delivered?
Orders placed before 2pm on a working day are dispatched the same day via Royal Mail Tracked 24, typically arriving in 1–2 working days, with tracking emailed on dispatch. UK shipping is free over £80, and EU shipping is available.
How do I pay, and is it secure?
We accept Pay by Bank — an instant, secure open-banking payment via Fena, where you authorise the payment in your own banking app and no card details are stored on our site. Manual UK bank transfer is available as a fallback. Orders are dispatched within 24 hours of cleared payment.
Does my order include a certificate of analysis?
Yes. Every order includes a batch-specific Certificate of Analysis documenting third-party HPLC purity and mass-spectrometry identity confirmation, emailed with your order confirmation. Previous batch CoAs are archived in our CoA library.

For in vitro research use only. Retatrutide is supplied solely as a research reagent for qualified professionals conducting in vitro or animal-model studies. It is not a medicinal product within the meaning of the Human Medicines Regulations 2012. It has not been evaluated by the MHRA or FDA. It is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale.

Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.